Prosecution Insights
Last updated: November 20, 2026
Application No. 19/182,381

QUANTITATIVE HORMONE AND CHEMICAL ANALYTE TEST RESULT SYSTEMS AND METHODS

Non-Final OA §103§112§DOUBLEPATENT
Filed
Apr 17, 2025
Priority
Jun 02, 2020 — provisional 63/033,767 +3 more
Examiner
SHIN, ANDREW
Art Unit
2612
Tech Center
2600 — Communications
Assignee
Easy Healthcare Corporation
OA Round
1 (Non-Final)
76%
Grant Probability
Favorable
1-2
OA Rounds
1y 2m
Est. Remaining
92%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allowance Rate
282 granted / 370 resolved
+14.2% vs TC avg
Strong +16% interview lift
Without
With
+15.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
14 currently pending
Career history
392
Total Applications
across all art units

Statute-Specific Performance

§101
6.5%
-33.5% vs TC avg
§103
60.0%
+20.0% vs TC avg
§102
18.1%
-21.9% vs TC avg
§112
12.1%
-27.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 370 resolved cases

Office Action

§103 §112 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1, 2, 4, 19, 22 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-3, 14, 16 of U.S. Patent No. 12,287,293. Although the claims at issue are not identical, they are not patentably distinct from each other because claim 3 of U.S. Patent No. 12,287,293 anticipates instant claim 1, as explained below. For example, please see the table below for a limitation-by-limitation mapping of claim 1. Claim 1 of instant application Claim 3 of U.S. Patent No. 12,287,293 (incorporating claims 1 and 2) A testing system comprising: (Claim 1) A testing system comprising: a test device including a test area including a visually identifiable test-line and a visually identifiable control-line formed in response to exposure to a tested substance; a test device including a test area including a visually identifiable test-line and a visually identifiable control-line formed in response to exposure to a tested substance; a user device including a camera, a processor, a display, and memory storing program instructions, wherein, in response to executing the program instructions, the processor: a user device including a camera, a processor, a display, and memory storing program instructions, wherein, in response to executing the program instructions, the processor: receives an image of the test device from the camera, the image including the test area, the visually identifiable test-line, and the visually identifiable control-line; receives an image of the test device from the camera, the image including the test area, the visually identifiable test-line, and the visually identifiable control-line; determines a numerical test-line value and a numerical control-line value based on the visually identifiable test-line and the visually identifiable control-line, respectively; determines a numerical test-line value and a numerical control-line value based on the visually identifiable test-line and the visually identifiable control-line, respectively; calculates a T/C ratio defined as a relative value of the numerical test-line value to the numerical control-line value; calculates a T/C ratio defined as a relative value of the numerical test-line value to the numerical control-line value; translates the T/C ratio into a quantitative level of an analyte in the tested substance; analyzes data points, wherein the data points include the T/C ratio, a quantitative level of an analyte corresponding to the T/C ratio, one or more T/C ratios of the analyte from previous test devices, additional T/C ratios, or additional quantitative levels of other analytes corresponding to the additional T/C ratios; analyzes data points, wherein the data points include the T/C ratio and/or quantitative level of the analyte and additional T/C ratios and/or additional quantitative levels of other analytes; presents a prediction of a fertility window, peak predicted fertility days, or period days. (Claim 1) presents information indicative of the data points, wherein the information includes a calendar and/or a graph including an ovulation cycle and/or hormone changes. (Claim 3) The system of claim 2, wherein the information comprises a prediction of a fertility window, peak predicted fertility days, or period days. Claim 2 of instant application corresponds to claim 2 of U.S. Patent No. 12,287,293. Claim 4 of instant application corresponds to claim 1 of U.S. Patent No. 12,287,293. Claim 19 of instant application corresponds to claim 16 of U.S. Patent No. 12,287,293. Claim 22 of instant application corresponds to claim 14 of U.S. Patent No. 12,287,293. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 8, 26 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 8 recites the “prediction includes the fertility window, the peak predicted fertility days, and the period days”. Claim 1 already recited this limitation. Claim 26 recites similar limitations as claim 8. Therefore, the same correction as claim 8 is required. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 2, 3, 5, 7, 11, 13, 19-35 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 2, 11, 20, 29 recite “the information”. There is insufficient antecedent basis for this limitation in the claim. Claims 3, 5, 7, 21, 23, 25 recite “the peak predicted fertility dates”. There is insufficient antecedent basis for this limitation in the claim. Claims 13, 31 recite “the background of the test area”. There is insufficient antecedent basis for this limitation in the claim. Claim 19 recites “the program instructions” in line 9. There is insufficient antecedent basis for this limitation in the claim. Claim 27 recites “the memory” in line 1. There is insufficient antecedent basis for this limitation in the claim. Claims 20, 22, 24-26, 28-35, depend on at least claim 19. Therefore, the claims 20, 22, 24-35 are rejected for at least the same reason as claim 19. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claim(s) 1, 4, 9, 10, 14-16, 19, 22, 27, 28, 32-34 is/are rejected under 35 U.S.C. 103 as being unpatentable over Erickson et al. (U.S. Patent Application 20160080548) in view of Busa et al. (U.S. Patent 10,823,746) and further in view of Martinez Hurtado (U.S. Patent Application 20190307432). In regards to claim 1, Erickson teaches a testing system [e.g. system for obtaining quantitative, colorimetric-based measurements of target analytes, 0126] comprising: a test device [Fig. 17A; e.g. test strip, 0177] including a test area [e.g. test region, 0142] including a visually identifiable test-line [e.g. test line, 0178-0180] and a visually identifiable control-line [e.g. control line, 0178-0180] formed in response to exposure to a tested substance [e.g. sweat, saliva, urine, or blood, 0016]; and a user device [Fig. 9C; e.g. smartphone such as iPhone 4, 0130] including a camera [Fig. 9C; e.g. camera, 0130], a processor [e.g. the smartphone inherently comprises a processor, 0014], a display [e.g. screen, 0145], and memory [e.g. the smartphone inherently comprises a memory, 0014] storing program instructions [e.g. programmed application, 0019], wherein, in response to executing the program instructions, the processor: receives an image of the test device from the camera [e.g. capturing an image by the smartphone camera, 0174, 0178], the image including the test area [e.g. test region, 0142], the visually identifiable test-line [e.g. test line, 0178-0180], and the visually identifiable control-line [e.g. control line, 0178-0180]; determines a numerical test-line value [Fig. 18A, 18B; e.g. local minima of test line, 0179-0180] and a numerical control-line value [Fig. 18A, 18B; e.g. local minima of control line, 0179-0180] based on the visually identifiable test-line and the visually identifiable control-line [Fig. 18A, 18B; e.g. based on the test and control lines, 0179-0180], respectively; calculates a T/C ratio [Fig. 19; e.g. T/C ratio, 0182] defined as a relative value of the numerical test-line value to the numerical control-line value [e.g. relative magnitude of the test and control lines, 0182]; Erickson does not explicitly teach analyzes data points, wherein the data points include the T/C ratio, a quantitative level of an analyte corresponding to the T/C ratio, one or more T/C ratios of the analyte from previous test devices, additional T/C ratios, or additional quantitative levels of other analytes corresponding to the additional T/C ratios; and presents a prediction of a fertility window, peak predicted fertility days, or period days. However, Busa teaches analyzes data points [e.g. calculating ratios of peak areas associated with test lines of the test device to a control line of the test device, c.13 L.51-63], wherein the data points include the T/C ratio [e.g. ratio associated with test line of the test device to the control line of the test device, c.13 L.51-63] or additional T/C ratios [e.g. other ratios associated with test lines of the test device to the control lines of the test device, c.13 L.51-63]. Therefore, it would have been obvious to one of ordinary skill in the art to have modified Erickson’s testing system with the features of analyzes data points, wherein the data points include the T/C ratio or additional T/C ratios; and in the same conventional manner as taught by Busa because Busa provides a method for visualizing the data in order to spot trends in the biological data [c.16 L.13-c.17 L.16]. Erickson as modified by Busa does not explicitly teach presents a prediction of a fertility window, peak predicted fertility days, or period days. However, Martinez Hurtado teaches presents a prediction of a fertility window [e.g. fertile window, 0064], peak predicted fertility days [e.g. most fertile days, 0064]. Therefore, it would have been obvious to one of ordinary skill in the art to have modified the combination of Erickson’s testing system and the teachings of Busa with the features of presents a prediction of a fertility window, peak predicted fertility days in the same conventional manner as taught by Martinez Hurtado because predicting a fertility window and peak predicted fertility days is well known and commonly used in the art of pregnancy testing systems. In regards to claim 4, Erickson teaches the system of claim 1, wherein the processor is further configured to translate the T/C ratio into the quantitative level [e.g. quantitative data, 0180] of the analyte in the tested substance [e.g. analyte concentration, 0180]. In regards to claim 9, Erickson teaches the system of claim 1, wherein the memory stores a data structure [e.g. storing in at least one of a readable file in the smartphone, 0053-0055] that relates the T/C ratio [Fig. 19; e.g. T/C ratio, 0182] to the quantitative level [e.g. quantitative data, 0180] of the analyte [e.g. analyte concentration, 0180]. In regards to claim 10, Erickson teaches the system of claim 1, wherein the characteristic being tested is the presence of one or more of a luteinizing hormone [e.g. luteinizing hormone, 0127, Table 1 located below 0190], a human chorionic gonadotropin [e.g. human chorionic gonadotropin, 0176], and estrogen [e.g. estrogen, 0127, Table 1 located below 0190] in the tested substance. In regards to claim 14, Erickson teaches the system of claim 1, wherein the test device is one of an ovulation [e.g. ovulation, 0127, Table 1 located below 0190], pregnancy [e.g. pregnancy test, 0176], estrogen [e.g. estrogen, 0127, Table 1 located below 0190] test device. In regards to claim 15, Erickson teaches the system of claim 1, wherein the tested substance is one of urine, blood, and saliva [e.g. sweat, saliva, urine, or blood, 0016]. In regards to claim 16, Erickson teaches the system of claim 1, wherein, in response to executing the program instructions, the processor selects the image from a stream of images received from the camera [e.g. selecting an array of pixels in each of the color images of the test region containing the analyte and the calibration region, 0028]. In regards to claim 19, the claim recites similar limitations as claim 1, but with the addition of a camera, including an image capture mechanism and a camera communication interface; a processor, including an image processing mechanism and a processor communication interface in communication with the camera communication interface; and a display controlled by the processor. Furthermore, Erickson teaches a camera [e.g. smartphone’s camera, 0113], including an image capture mechanism [e.g. image recording, 0126] and a camera communication interface [e.g. app, 0109]; a processor [e.g. a smartphone must inherently have at least one processor, 0109], including an image processing mechanism [e.g. image processing algorithm, 0124] and a processor communication interface [e.g. app, 0109] in communication with the camera communication interface; and a display [e.g. smartphone screen, 0171] controlled by the processor. Therefore, the same rationale as claim 1 is applied. In regards to claim 22, the claim recites similar limitations as claim 4. Therefore, the same rationale as claim 4 is applied. In regards to claim 27, the claim recites similar limitations as claim 9. Therefore, the same rationale as claim 9 is applied. In regards to claim 28, the claim recites similar limitations as claim 10. Therefore, the same rationale as claim 10 is applied. In regards to claim 32, the claim recites similar limitations as claim 14. Therefore, the same rationale as claim 14 is applied. In regards to claim 33, the claim recites similar limitations as claim 15. Therefore, the same rationale as claim 15 is applied. In regards to claim 34, the claim recites similar limitations as claim 16. Therefore, the same rationale as claim 16 is applied. Claim(s) 2, 11, 20, 29 is/are rejected under 35 U.S.C. 103 as being unpatentable over Erickson et al. (U.S. Patent Application 20160080548) in view of Busa et al. (U.S. Patent 10,823,746) and further in view of Martinez Hurtado (U.S. Patent Application 20190307432) as applied to claims 1, 19 above, and further in view of Divaraniya et al. (U.S. Patent Application 20210264604). In regards to claim 2, Erickson as modified by Busa and Martinez Hurtado does not explicitly teach the system of claim 1, wherein the information further includes the ovulation cycle and/or the hormone changes over a plurality of months. However, Divaraniya teaches the system of claim 1, wherein the information further includes the ovulation cycle [e.g. a summary report of her current cycle or cycles over a plurality of months, 0175] and/or the hormone changes over a plurality of months [e.g. data on her menstrual cycles over a plurality of months includes changes in her hormones such as LH, estradiol, and/or progesterone, 0174-0175, also see 0148]. Therefore, it would have been obvious to one of ordinary skill in the art to have modified the combination of Erickson’s testing system and the teachings of Busa and Martinez Hurtado with the features of wherein the information further includes the ovulation cycle and/or the hormone changes over a plurality of months in the same conventional manner as taught by Divaraniya because Divaraniya provides a method that accurately forecasts ovulation for a user [0172]. In regards to claim 11, Erickson as modified by Busa and Martinez Hurtado does not explicitly teach the system of claim 1, further comprising a plurality of test devices, each test device including a test area including a visually identifiable test-line and a visually identifiable control-line formed in response to exposure to a tested substance, wherein the processor is configured to: receive a plurality of images of the test devices from the camera, each image including the test area, the visually identifiable test-line, and the visually identifiable control-line; determine a numerical test-line value and a numerical control-line value based on the visually identifiable test-line and the visually identifiable control-line, respectively, for each image; calculate a T/C ratio for each image, the T/C ratio defined as a relative value of the numerical test-line value to the numerical control-line value; and present the information comprising the prediction. However, Divaraniya teaches the system of claim 1, further comprising a plurality of test devices [e.g. two more lateral flow devices, 0008], each test device [e.g. each lateral flow device, 0008] including a test area [e.g. detection region, 0446] including a visually identifiable test-line [e.g. test area with an embedded test line, 0446, also see 0112] and a visually identifiable control-line [e.g. control area with an embedded control line, 0446, also see 0112] formed in response to exposure to a tested substance [e.g. biological sample fluid, such as urine, blood, serum, or saliva, 0109, 0111-0112], wherein the processor [e.g. processor, 0005] is configured to: receive a plurality of images of the test devices from the camera [e.g. each test scanned with the camera of a smartphone, 0130, 0422], each image including the test area, the visually identifiable test-line, and the visually identifiable control-line [e.g. each image includes a detection region comprising a test area with an embedded test line and a control area with an embedded control line, 0165, also see 0446]; determine a numerical test-line value [e.g. quantitative test line intensity result, 0257] and a numerical control-line value [e.g. control line (CL) values, 0082] based on the visually identifiable test-line and the visually identifiable control-line, respectively, for each image; calculate a T/C ratio for each image, the T/C ratio defined as a relative value of the numerical test-line value to the numerical control-line value [e.g. Comparing pixel intensities of the test area and the control area of a lateral flow device. The comparing can comprise normalizing pixel intensities between the test area and the control area, thereby quantifying the analyte, 0163]; and present the information comprising the prediction [e.g. predict the fertile window of women and ovulation, 0138, 0140, 0147]. Therefore, it would have been obvious to one of ordinary skill in the art to have modified the combination of Erickson’s testing system and the teachings of Busa and Martinez Hurtado with the features of a plurality of test devices, each test device including a test area including a visually identifiable test-line and a visually identifiable control-line formed in response to exposure to a tested substance, wherein the processor is configured to: receive a plurality of images of the test devices from the camera, each image including the test area, the visually identifiable test-line, and the visually identifiable control-line; determine a numerical test-line value and a numerical control-line value based on the visually identifiable test-line and the visually identifiable control-line, respectively, for each image; calculate a T/C ratio for each image, the T/C ratio defined as a relative value of the numerical test-line value to the numerical control-line value; and present the information comprising the prediction; in the same conventional manner as taught by Divaraniya because Divaraniya provides a method that accurately predicts a woman’s fertile days forecasts ovulation for a user [0138, 0172]. In regards to claim 20, the claim recites similar limitations as claim 2. Therefore, the same rationale as claim 2 is applied. In regards to claim 29, the claim recites similar limitations as claim 11. Therefore, the same rationale as claim 11 is applied. Claim(s) 8, 26 is/are rejected under 35 U.S.C. 103 as being unpatentable over Erickson et al. (U.S. Patent Application 20160080548) in view of Busa et al. (U.S. Patent 10,823,746) and further in view of Martinez Hurtado (U.S. Patent Application 20190307432) as applied to claim 1 above, and further in view of Lafon et al. (U.S. Patent Application 20200000441). In regards to claim 8, Erickson as modified by Busa does not explicitly teach the system of claim 1, wherein the prediction includes the fertility window, the peak predicted fertility days, and the period days. However, Martinez Hurtado teaches the system of claim 1, wherein the prediction includes the fertility window [e.g. fertile window, 0064], the peak predicted fertility days [e.g. most fertile days, 0064]. Therefore, it would have been obvious to one of ordinary skill in the art to have modified the combination of Erickson’s testing system and the teachings of Busa with the features of wherein the prediction includes the fertility window, the peak predicted fertility in the same conventional manner as taught by Martinez Hurtado because predicting a fertility window and peak predicted fertility days is well known and commonly used in the art of pregnancy testing systems. Erickson as modified by Busa and Martinez Hurtado does not explicitly teach wherein the prediction includes the period days. However, Lafon teaches wherein the prediction includes the period days [e.g. A calendar with the likely start date of the menses, and the most likely date of ovulation as well as the fertile window. The view can also indicate predicted times or dates for future menstruation based on the prediction values, 0021-0022]. Therefore, it would have been obvious to one of ordinary skill in the art to have modified the combination of Erickson’s testing system and the teachings of Busa and Martinez Hurtado with the features of wherein the prediction includes the period days in the same conventional manner as taught by Lafon because predicting the period days is well known and commonly used in the art of pregnancy testing systems. In regards to claim 26, the claim recites similar limitations as claim 8. Therefore, the same rationale as claim 8 is applied. Claim(s) 17, 35 is/are rejected under 35 U.S.C. 103 as being unpatentable over Erickson et al. (U.S. Patent Application 20160080548) in view of Busa et al. (U.S. Patent 10,823,746) and further in view of Martinez Hurtado (U.S. Patent Application 20190307432) as applied to claims 1, 19 above, and further in view of Pulitzer et al. (U.S. Patent Application 20190384890). In regards to claim 17, Erickson as modified by Busa and Martinez Hurtado does not explicitly teach the system of claim 1, wherein the image includes a visually identifiable portion of the test device, further wherein, in response to executing the program instructions, the processor identifies a model of the test device based on the visually identifiable portion of the test device. However, Pulitzer teaches the system [e.g. system, 0103] of claim 1, wherein the image [Fig. 22; e.g. image, 0102] includes a visually identifiable portion [e.g. test function indicators, 0102] of the test device [e.g. testing device, 0102], further wherein, in response to executing the program instructions [e.g. mobile application, 0102], the processor [e.g. mobile device inherently has a processor, 0102] identifies a model of the test device [e.g. identify the types of test for which the testing device is configured, 0102] based on the visually identifiable portion of the test device. Therefore, it would have been obvious to one of ordinary skill in the art to have modified the combination of Erickson’s testing system and the teachings of Busa and Martinez Hurtado with the features of wherein the image includes a visually identifiable portion of the test device, further wherein, in response to executing the program instructions, the processor identifies a model of the test device based on the visually identifiable portion of the test device in the same conventional manner as taught by Pulitzer because Pulitzer provides a method for potential early identification of pregnancy and risk of morbidity, allowing for medical attention to be sought much more quickly [0083]. In regards to claim 35, the claim recites similar limitations as claim 17. Therefore, the same rationale as claim 17 is applied. Claim(s) 18 is/are rejected under 35 U.S.C. 103 as being unpatentable over Erickson et al. (U.S. Patent Application 20160080548) in view of Busa et al. (U.S. Patent 10,823,746) and further in view of Martinez Hurtado (U.S. Patent Application 20190307432) as applied to claim 1 above, and further in view of Polwart et al. (U.S. Patent Application 20140154789). In regards to claim 18, Erickson as modified by Busa and Martinez Hurtado does not explicitly teach the system of claim 17, wherein the processor identifies the visually identifiable test-line and the visually identifiable control-line by identifying a location, edges, and line width within a test area that correspond to a defined test-line and a defined control-line for the identified model of the test device. However, Polwart teaches the system [e.g. testing apparatus, Abstract] of claim 17, wherein the processor [e.g. processor, Abstract] identifies the visually identifiable test-line and the visually identifiable control-line [e.g. identify the presence/absence of the control line, 0069] by identifying a location [e.g. identify the expected location of the test line, 0069], edges [e.g. identify the location of the result region which includes edges, 0069], and line width [e.g. magnitude of the test and control lines, 0069] within a test area [e.g. result region, 0069] that corresponds to a defined test-line and a defined control-line [e.g. quantified test or control lines, 0032] for the identified model of the test device [e.g. testing apparatus configured for performing a lateral flow immunoassay, 0014]. Therefore, it would have been obvious to one of ordinary skill in the art to have modified the combination of Erickson’s testing system and the teachings of Busa and Martinez Hurtado with the features of wherein the processor identifies the visually identifiable test-line and the visually identifiable control-line by identifying a location, edges, and line width within a test area that corresponds to a defined test-line and a defined control-line for the identified model of the test device in the same conventional manner as taught by Polwart because Polwart provides a method that differs from known methods in that it uses only the inbuilt hardware of the device requiring no external hardware or modifications to the electronics or infrastructure of the device. A key development is the inclusion of the image processing on the device, enabling the device to be operated stand alone without internet or phone connection if desired and also for "real time" feedback to the user on the position, orientation, and image quality SO that the operator can quickly capture an image of adequate quality, before any window of opportunity for a valid test result may have elapsed. Processing directly on the device enables the maximum image quality to be used. "Pre-filters" can be applied to discard irrelevant portions of the image such that processing time is minimized [0050]. Allowable Subject Matter Claim 3, 5, 7, 12, 13, 21, 23-25, 30, 31 would be allowable if rewritten to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action and to include all of the limitations of the base claim and any intervening claims. Claims 6, 12 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. In regards to claim 3, the prior art of record fails to teach or suggest the system of claim 1, wherein the data points comprise a plurality of T/C ratios measured over a plurality of menstrual cycles, and wherein the processor is further configured to: determine an indication of an ovulation time based on the data points; and determine a predicted ovulation time for subsequent menstrual cycles, wherein the prediction of the fertility window, the peak predicted fertility dates, or period days includes the ovulation time for subsequent menstrual cycles. In regards to claim 5, the prior art of record fails to teach or suggest the system of claim 4, wherein the data points comprise a plurality of quantitative levels of the analyte measured over a plurality of menstrual cycles, and wherein the processor is further configured to: determine an indication of an ovulation time based on the data points; and determine a predicted ovulation time for subsequent menstrual cycles, wherein the prediction of the fertility window, the peak predicted fertility dates, or period days includes the ovulation time for subsequent menstrual cycles. In regards to claim 6, the claim depends on at least claim 5. Therefore, the claim is allowable for at least the same reason as claim 5 if rewritten in independent form including all of the limitations of the base claim and any intervening claims. In regards to claim 7, the prior art of record fails to teach or suggest the system of claim 1, wherein the processor is further configured to: determine hormone and/or ovulation patterns based on the data points; determine peak hormone days based on the hormone and/or ovulation patterns; and display predicted peak hormone days of subsequent menstrual cycles, wherein the prediction of the fertility window, the peak predicted fertility dates, or period days includes the predicted peak hormone days. In regards to claim 12, the prior art of record fails to teach or suggest the system of claim 11, wherein, in response to executing the program instructions, the processor further: creates, for each image, a test-line greyscale representation of the visually identifiable test-line and a control-line greyscale representation of the visually identifiable control-line; determines, for each image, a numerical test-line value based on a test-line darkness value of the test-line greyscale representation of the visually identifiable test-line; and determines, for each image, a numerical control-line value based on a test-line darkness value of the test-line greyscale representation of the visually identifiable test-line. In regards to claim 13, the claim depends on at least claim 12. Therefore, claim 13 is allowable for at least the same reason as claim 12 if rewritten to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action and to include all of the limitations of the base claim and any intervening claims. In regards to claim 21, the claim recites similar limitations as claim 3. Therefore, claim 21 is allowable for at least the same reason as claim 3 if rewritten to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action and to include all of the limitations of the base claim and any intervening claims. In regards to claim 23, the claim recites similar limitations as claim 5. Therefore, claim 23 is allowable for at least the same reason as claim 5 if rewritten to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action and to include all of the limitations of the base claim and any intervening claims. In regards to claim 24, the claim depends on at least claim 23. Therefore, the claim is allowable for at least the same reason as claim 23 if rewritten to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action and to include all of the limitations of the base claim and any intervening claims. In regards to claim 25, the claim recites similar limitations as claim 7. Therefore, claim 25 is allowable for at least the same reason as claim 7 if rewritten to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action and to include all of the limitations of the base claim and any intervening claims. In regards to claim 30, the claim recites similar limitations as claim 12. Therefore, claim 30 is allowable for at least the same reason as claim 12 if rewritten to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action and to include all of the limitations of the base claim and any intervening claims. In regards to claim 31, the claim depends on at least claim 30. Therefore, claim 31 is allowable for at least the same reason as claim 30 if rewritten to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action and to include all of the limitations of the base claim and any intervening claims. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANDREW SHIN whose telephone number is (571)270-5764. The examiner can normally be reached Monday - Friday from 11:00AM to 7:00PM EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Said Broome can be reached at 571-272-2931. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ANDREW SHIN/Examiner, Art Unit 2612 /Said Broome/Supervisory Patent Examiner, Art Unit 2612
Read full office action

Prosecution Timeline

Apr 17, 2025
Application Filed
Oct 28, 2026
Non-Final Rejection mailed — §103, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12802358
METHOD AND DEVICE FOR GENERATING CONDYLAR MOVEMENT ENVELOPE SURFACE OF TEMPOROMANDIBULAR JOINT BASED ON FACIAL PARAMETERS
2y 1m to grant Granted Nov 17, 2026
Patent 12802341
IMAGE GENERATION APPARATUS AND CONTROL METHOD FOR IMAGE GENERATION APPARATUS
2y 1m to grant Granted Nov 17, 2026
Patent 12784302
METHOD AND DEVICE FOR CHECKING VALUE DOCUMENTS AND METHOD AND DEVICE FOR GENERATING CHECKING PARAMETERS FOR THE CHECKING METHOD
2y 11m to grant Granted Nov 03, 2026
Patent 12784237
INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD, AND PRESENTATION CONTROL APPARATUS
2y 1m to grant Granted Nov 03, 2026
Patent 12762830
METHOD FOR EFFECT GENERATION AND APPARATUS, COMPUTER DEVICE, AND STORAGE MEDIUM
2y 4m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
76%
Grant Probability
92%
With Interview (+15.8%)
2y 9m (~1y 2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 370 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month